The original success of Viagra undeniably reshaped the drug landscape, but investing in companies primarily reliant on unbranded versions presents a uncertain picture. While early returns were impressive, the cessation of patents and the rise of less expensive alternatives have weakened sales. Therefore, a thorough analysis of ongoing financial per